Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Edwards secures FDA approval for tricuspid valve repair system
The US Food and Drug Administration (FDA) has approved Edwards Lifesciences’ tricuspid valve repair system, PASCAL Precision. The transcatheter medical device …
-
MSD’s Keytruda and Padcev combination receives EC approval
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for …
-
Abbott secures CE Mark for Cologuard Plus cancer test
Abbott has secured CE Mark approval under the EU’s In Vitro Diagnostic Medical Devices Regulation (IVDR) for its Cologuard Plus …
-
AstraZeneca and Oracle collaborate to test AI in clinical trial recruitment
AstraZeneca and Oracle have signed a non-binding agreement to investigate how AI and real-world data can help medical teams recruit …
-
Sanofi and ScionxBio partner on mRNA therapies
Sanofi has signed a global licensing and strategic collaboration agreement with UK-based biotechnology company ScionxBio to develop long-acting messenger ribonucleic …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Sanofi and ScionxBio partner on mRNA therapies
Sanofi has signed a global licensing and strategic collaboration agreement with UK-based biotechnology company ScionxBio to develop long-acting messenger ribonucleic …
-
Estuary secures $103m to advance kidney disease gene therapies
US-based genetic medicines developer Estuary Biotherapeutics has launched after securing $103m in total committed financing for developing targeted gene therapies …
-
USC initiates trial of blood test for breast cancer
USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has initiated a Phase I clinical trial to determine …
-
Cyrano’s Phase II trial of CYR-064 meets primary safety endpoint
Cyrano Therapeutics has reported that the Phase II FLAVOR study of CYR-064 met its primary safety endpoint in patients with …
-
GE HealthCare secures CE mark for MINItrace Magni cyclotron
GE HealthCare has secured CE Mark certification for its MINItrace Magni cyclotron and broadened its PETtrace Solid Target Platform to …
-
Merz concludes enrolment in Phase III Xeomin trials for migraine
Merz Therapeutics has concluded patient enrolment in MINT-C and MINT-E, two global Phase III clinical trials assessing Xeomin (incobotulinumtoxinA) for …
-
Transcripta Bio, Mayo Clinic join force on ALS therapies
Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic …
-
FDA approves Stryker’s Sonopet 3 surgical platform
The US Food and Drug Administration (FDA) has granted 510(k) clearance to Stryker for Sonopet 3, the medical technology company's …
-
Alentis and PinotBio partner to develop claudin-1 oncology ADCs
Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for …
-
Pilatus doses first patient in Phase I PLT012 trial for HCC
Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing …
